Trial Profile
A Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal™ (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Remestemcel-L (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Sponsors Osiris Therapeutics
- 25 May 2020 Results presented in the Mesoblast Media Release.
- 25 May 2020 According to a Mesoblast media release, data from this trial were published in peer-reviewed articles and an accompanying editorial in the May issue of Biology of Blood and Marrow Transplantation, the official publication of the American Society for Transplantation and Cellular Therapy.
- 20 May 2014 New trial record